Anti‐Myelin Associated Glycoprotein Neuropathy With Immune Checkpoint Inhibitor Use

Key Points

• This study aims to explore the relationship between anti-myelinated associated glycoprotein neuropathy and the use of immune checkpoint inhibitors.
• Observed cases of neuropathy in patients receiving immune checkpoint inhibitors.
• Analyzed potential correlations with clinical symptoms and treatment history.
• Identified instances of neuropathy potentially linked to immune checkpoint inhibitor treatment.
• Found symptoms consistent with anti-myelinated associated glycoprotein neuropathy.